SCHEMBL3600670

SCHEMBL3600670

CN1C(=O)CCc2c([NH])cccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 8/20 0.40
BRPF1 P55201 1/20 0.40
HTR1A P08908 2/20 0.39
HTR1D P28221 2/20 0.39
HTR1B P28222 2/20 0.39
SLC6A4 P31645 2/20 0.39
KCNH2 Q12809 2/20 0.39
BRD4 O60885 2/20 0.36
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
CYP17A1 P05093 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP19A1 P11511 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SRD5A1 P18405 1/20 0.36
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL424738 0.81 NOTUM (0.47) TRPV1BRPF1HTR1AHTR1DHTR1B
SCHEMBL16110071 0.81 TRPV1 (0.40) TRPV1BRPF1HTR1AHTR1DHTR1B
SCHEMBL8557973 0.80 NOTUM (0.49) TRPV1BRPF1HTR1AHTR1DHTR1B
SCHEMBL9959955 0.80 NOTUM (0.49) TRPV1GABRA1GABRG2GABRB3GABRA5
SCHEMBL3600672 0.80 TRPV1 (0.42) TRPV1BRPF1HTR1AHTR1DHTR1B
SCHEMBL24265742 0.80 TRPV1 (0.39) TRPV1BRPF1HTR1AHTR1DHTR1B
SCHEMBL9653024 0.80 TRPV1 (0.42) TRPV1BRPF1HTR1AHTR1DHTR1B
SCHEMBL20148797 0.77 FAAH (0.41) TRPV1BRPF1HTR1AHTR1DHTR1B
SCHEMBL13545354 0.77 TRPV1 (0.48) TRPV1BRPF1HTR1AHTR1DHTR1B
SCHEMBL15086480 0.77 TRPV1 (0.38) TRPV1BRPF1HTR1AHTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 TRPV1 2518/4885BRPF1 2744/4885HTR1A 1118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.